Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Combining golimumab with methotrexate reduced corticosteroid reliance and maintained efficacy in psoriatic arthritis.

Adding Golimumab to Treatment Regimen Reduced Rescue Corticosteroid Use in People With Early PsA

In this feature, 3 experts discuss the management of 2 overlapping conditions: psoriasis and psoriatic arthritis.

Closing the Gap: Collaborating Care to Improve Outcomes in Psoriasis and Psoriatic Arthritis

Recent phase 3 trials reveal promising results for Duravancinib in treating psoriatic arthritis, showcasing efficacy and a strong safety profile.

Validating Deucravacitinib’s Anticipated Expansion to Psoriatic Arthritis, with Philip Mease, MD

DRESS-PS extension study shows patients maintaining low disease activity while gradually reducing TNF inhibitor doses over 24 months.

TNF Inhibitor Tapering Safe, Effective for 2 Years in PsA and AxSpA

Zasocitinib recently demonstrated better ACR responses than placebo in new trial data.

TYK2 Inhibitor Zasocitinib’s Potential for Psoriatic Arthritis, with Andrew Sharobeem, DO

The APEX study presents the results of 2 dosing regimens of guselkumab (Q4W and Q8W) in biologic-naïve patients with psoriatic arthritis (PsA).

Study Highlights Results of 2 Dosing Regimens of Guselkumab on PsA Symptoms at 24 Weeks

The rheumatology month in review emphasizes new research in psoriatic arthritis treatments and data from EULAR 2025.

6 Rheumatology Headlines You Missed in July 2025

Guselkumab shows promise as the first IL-23 inhibitor to significantly reduce joint damage in active psoriatic arthritis.

J&J Seeks New Guselkumab Label Reflecting Inhibition of PsA Joint Damage 

New phase 3 trials reveal tildrakizumab 100mg significantly improves symptoms in active psoriatic arthritis, offering hope for effective treatment options.

Pivotal Tildrakizumab Trials Meet Endpoint for Psoriatic Arthritis

Mease described his real-world experience with using bimekizumab in the clinic for treating PsA and AxSpA.

Real-World Benefits of Bimekizumab for Psoriatic Arthritis, AxSpA, with Philip Mease, MD

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.